Floatz logo

Sra-333

Migraine Headache

Eisai Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Migraine Headache cohort.

Asset / SponsorPhaseRating
NADOLOL
Ohio University
Phase 4BBB
Dihydroergotamine mesylate
Impel Pharmaceuticals
Phase 3BB
Capecitabine
Ohio University
Phase 4BB
DICLOFENAC
Scripps Health
Phase 4BB
Dfn-15
BioDelivery Sciences International
Phase 3BB

View all 17 →

Same molecule, other indications

Sra-333 is also rated in:

Dementia With Lewy Bodies (DLB)Dormant
BBB
Indicative ·
76 / 100
View asset →
DementiaDormant
BBB
Indicative ·
74 / 100
View asset →
Alzheimer's DiseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →